Sigma Planning Corp Abb Vie Inc. Transaction History

Sigma Planning Corp

$3.22 Billion
Q3 2024

A detailed history of Sigma Planning Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Sigma Planning Corp holds 109,462 shares of ABBV stock, worth $19.7 Million. This represents 0.67% of its overall portfolio holdings.

Number of Shares

109,462

Previous 110,449 0.89%

Holding current value

$19.7 Million

Previous $18.9 Million 14.1%

% of portfolio

0.67%

Previous 0.6%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$163.84 - $199.33 $161,710 - $196,738	-987 Reduced 0.89%	109,462 $21.6 Million
Q2 2024 Aug 05, 2024	SELL	$154.79 - $180.76 $2.17 Million - $2.54 Million	-14,051 Reduced 11.29%	110,449 $18.9 Million
Q1 2024 May 01, 2024	BUY	$159.82 - $182.1 $7.53 Million - $8.59 Million	47,145 Added 60.95%	124,500 $22.7 Million
Q4 2023 Feb 01, 2024	SELL	$137.6 - $154.97 $6.85 Million - $7.72 Million	-49,803 Reduced 39.17%	77,355 $12 Million
Q3 2023 Nov 06, 2023	BUY	$133.59 - $154.65 $4.62 Million - $5.35 Million	34,586 Added 37.36%	127,158 $19 Million
Q2 2023 Aug 01, 2023	SELL	$132.51 - $164.9 $1.34 Million - $1.67 Million	-10,125 Reduced 9.86%	92,572 $12.5 Million
Q1 2023 May 05, 2023	SELL	$144.61 - $166.54 $523,632 - $603,041	-3,621 Reduced 3.41%	102,697 $16.4 Million
Q4 2022 Jan 24, 2023	SELL	$138.31 - $165.87 $23,651 - $28,363	-171 Reduced 0.16%	106,318 $0
Q3 2022 Nov 10, 2022	BUY	$134.21 - $153.93 $392,161 - $449,783	2,922 Added 2.82%	106,489 $14.3 Million
Q2 2022 Aug 11, 2022	SELL	$137.62 - $174.96 $3.01 Million - $3.83 Million	-21,878 Reduced 17.44%	103,567 $15.9 Million
Q1 2022 Apr 20, 2022	SELL	$131.98 - $163.75 $472,356 - $586,061	-3,579 Reduced 2.77%	125,445 $20.3 Million
Q4 2021 Feb 02, 2022	BUY	$107.43 - $135.93 $521,142 - $659,396	4,851 Added 3.91%	129,024 $17.5 Million
Q3 2021 Oct 28, 2021	BUY	$106.4 - $120.78 $96,824 - $109,909	910 Added 0.74%	124,173 $13.4 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $903,543 - $1.01 Million	8,588 Added 7.49%	123,263 $13.9 Million
Q1 2021 May 06, 2021	SELL	$102.3 - $112.62 $695,128 - $765,252	-6,795 Reduced 5.59%	114,675 $12.4 Million
Q4 2020 Feb 09, 2021	BUY	$80.49 - $108.67 $286,061 - $386,213	3,554 Added 3.01%	121,470 $13 Million
Q3 2020 Nov 03, 2020	BUY	$85.91 - $100.83 $677,486 - $795,145	7,886 Added 7.17%	117,916 $10.3 Million
Q2 2020 Jul 31, 2020	BUY	$73.37 - $98.18 $1.96 Million - $2.63 Million	26,754 Added 32.13%	110,030 $10.8 Million
Q1 2020 May 01, 2020	SELL	$64.5 - $97.79 $6,708 - $10,170	-104 Reduced 0.12%	83,276 $6.35 Million
Q4 2019 Feb 03, 2020	BUY	$72.13 - $90.25 $367,213 - $459,462	5,091 Added 6.5%	83,380 $7.38 Million
Q3 2019 Nov 01, 2019	BUY	$62.98 - $75.72 $398,222 - $478,777	6,323 Added 8.79%	78,289 $5.93 Million
Q2 2019 Aug 01, 2019	BUY	$65.7 - $83.98 $400,441 - $511,858	6,095 Added 9.25%	71,966 $5.23 Million
Q1 2019 May 01, 2019	BUY	$77.14 - $90.79 $673,509 - $792,687	8,731 Added 15.28%	65,871 $5.31 Million
Q4 2018 Jan 31, 2019	SELL	$77.85 - $96.01 $687,649 - $848,056	-8,833 Reduced 13.39%	57,140 $5.27 Million
Q3 2018 Nov 07, 2018	BUY	$88.91 - $98.84 $322,743 - $358,789	3,630 Added 5.82%	65,973 $6.24 Million
Q2 2018 Aug 02, 2018	BUY	$89.78 - $106.23 $442,525 - $523,607	4,929 Added 8.59%	62,343 $5.78 Million
Q1 2018 May 11, 2018	BUY	$92.01 - $123.21 $89,801 - $120,252	976 Added 1.73%	57,414 $5.43 Million
Q4 2017 Feb 07, 2018	BUY	$89.56 - $98.21 $104,516 - $114,611	1,167 Added 2.11%	56,438 $5.46 Million
Q3 2017 Nov 06, 2017	BUY	$69.85 - $89.22 $3.86 Million - $4.93 Million	55,271	55,271 $4.91 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.

Account

Sigma Planning Corp Abb Vie Inc. Transaction History